Lindheimer M D, Davison J M
Department of Obstetrics & Gynecology, University of Chicago, IL.
Eur J Endocrinol. 1995 Feb;132(2):133-43. doi: 10.1530/eje.0.1320133.
This review stresses changes in osmoregulation as well as the secretion and metabolism of arginine vasopressin during pregnancy, focusing on human gestation. Pregnant women experience a decrease in body tonicity, plasma osmolality decreasing immediately after conception to a nadir approximately 10 mosmol/kg below non-pregnant levels early in pregnancy, after which a new steady state is maintained until term. Data from both human and rodent gestation have led to a formation of how these changes occur. The osmotic thresholds for thirst and antidiuretic hormone release decrease in parallel. Lowering the threshold to drink stimulates increased water intake and dilution of body fluids. Because arginine vasopressin (AVP) release is not suppressed at the usual level of body tonicity, the hormone continues to circulate and the ingested water is retained. Plasma osmolality declines until it is below the osmotic thirst threshold, and a new steady state with little change in water turnover is established. Pregnancy is characterized by increments in intravascular volume, but volume-sensing AVP release mechanisms appear to adjust as gestation progresses so that each new volume status is "sensed" as normal. The metabolic clearance of AVP increases fourfold, the rise paralleling that of circulating cystine aminopeptidase (vasopressinase), and enzyme produced by the placenta. Furthermore, the disposal rate of 1-deamino-8-D-AVP, and AVP analogue resistant to inactivation by vasopressinase, is unaltered in pregnancy. Thus, the increase in AVP's metabolism and the high circulating aminopeptidase levels have been implicated in certain forms of transient diabetes insipidus that occur in late pregnancy. Finally, mechanisms responsible for the altered osmoregulation in pregnancy are obscure, but chorionic gonadotropin and relaxin may be implicated in the changes.
本综述着重探讨孕期精氨酸加压素的分泌、代谢以及渗透调节的变化,重点关注人类妊娠。孕妇的身体张力降低,血浆渗透压在受孕后立即下降,在妊娠早期降至最低点,比非孕期水平低约10 mosmol/kg,此后维持新的稳态直至足月。来自人类和啮齿动物妊娠的数据揭示了这些变化的发生机制。口渴和抗利尿激素释放的渗透阈值同步降低。饮水阈值降低刺激水摄入量增加和体液稀释。由于在通常的身体张力水平下精氨酸加压素(AVP)的释放未被抑制,该激素继续循环,摄入的水得以保留。血浆渗透压下降,直至低于渗透口渴阈值,从而建立起水周转率变化不大的新稳态。妊娠的特征是血管内容量增加,但随着妊娠进展,容量感应性AVP释放机制似乎会进行调整,以便将每个新的容量状态“感知”为正常。AVP的代谢清除率增加四倍,其升高与循环中的胱氨酸氨基肽酶(加压素酶)平行,后者由胎盘产生。此外,1-去氨基-8-D-AVP(一种对加压素酶失活具有抗性的AVP类似物)的处置率在孕期未发生改变。因此,AVP代谢的增加和循环中氨基肽酶水平的升高与妊娠晚期发生的某些形式的暂时性尿崩症有关。最后,孕期渗透调节改变的机制尚不清楚,但绒毛膜促性腺激素和松弛素可能与这些变化有关。